Human APRIL / TNFSF13 Protein

<strong>Human APRIL / TNFSF13 Protein</strong>_x000D_ <strong>Catalog number:</strong> B2017144_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20℃_x000D_ <strong>Keywords:</strong> Human APRIL / TNFSF13 Protein_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy N Engl J Med. 2024 Jan 4;390(1):20-31._x000D_ 2: Dhillon S. Telitacicept: First Approval Drugs. 2021 Sep;81(14):1671-1675._x000D_ 3: Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy Kidney Int. 2019 Jul;96(1):104-116._x000D_ 4: Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival Annu Rev Immunol. 2003;21:231-64._x000D_ 5: Cai S, Hu Z, Chen Y, Chen Y, Ming B, Gao R, Li Z, Ye C, Zhong J, Dong L. BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept Ann Rheum Dis. 2023 Jun;82(6):881-883._x000D_ 6: Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy Kidney Int. 2020 Feb;97(2):340-349._x000D_ 7: Evans LS, Lewis KE, DeMonte D, Bhandari JG, Garrett LB, Kuijper JL, Ardourel D, Wolfson MF, Debrot S, Mudri S, Kleist K, Griffin LL, Hebb L, Sanderson RJ, Wang N, Seaberg M, Chunyk AG, Yang J, Hong Y, Maria Z, Messenheimer DJ, Holland PM, Peng SL, Rixon MW, Dillon SR. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases Arthritis Rheumatol. 2023 Jul;75(7):1187-1202._x000D_ 8: Tsiantoulas D, Eslami M, Obermayer G, Clement M, Smeets D, Mayer FJ, Kiss MG, Enders L, Weißer J, Göderle L, Lambert J, Frommlet F, Mueller A, Hendrikx T, Ozsvar-Kozma M, Porsch F, Willen L, Afonyushkin T, Murphy JE, Fogelstrand P, Donzé O, Pasterkamp G, Hoke M, Kubicek S, Jørgensen HF, Danchin N, Simon T, Scharnagl H, März W, Borén J, Hess H, Mallat Z, Schneider P, Binder CJ. APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans Nature. 2021 Sep;597(7874):92-96._x000D_ 9: Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders Semin Immunol. 2006 Oct;18(5):305-17._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/37958571">10: Jung HH, Kim JY, Cho EY, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Im YH. A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Int J Mol Sci. 2023 Oct 25;24(21):15576. </a>_x000D_ _x000D_ <strong>Products Related to Human APRIL / TNFSF13 Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>